PSG.DE PharmaSGP (XETRA) €29.00 on 29 Jan 2026: Oversold bounce in play, watch €31.50 target
We see PSG.DE stock trading at €29.00 on XETRA on 29 Jan 2026, setting up an intraday oversold bounce. Volume is 12,424.00 shares versus an average of 5,399.00, giving a relative volume of 2.30. Price sits near the 50-day average of €28.52, which acts as immediate support. Given low net debt and solid margins, we view a short-term recovery toward resistance as probable, but valuation and inventory metrics call for caution.
Intraday price action and bounce setup for PSG.DE stock
Price opened at €28.80 and ranged €28.60–€29.00 intraday. The stock trades on XETRA in Germany and touched the 50-day mean at €28.52, forming buyer interest near that level. High traded volume of 12,424.00 versus average 5,399.00 supports a quick mean-reversion trade today.
Fundamentals snapshot: PharmaSGP Holding SE (PSG.DE) on XETRA
PharmaSGP (PSG.DE) shows EPS €1.68 and a trailing P/E of 17.26. Market cap is €333,862,500.00 with 11,512,500.00 shares outstanding. Key metrics include price-to-sales 3.55, price-to-book 9.12, current ratio 2.68, and ROE 44.29%, signaling strong returns but rich book valuation.
Technicals and the oversold bounce thesis
The bounce thesis rests on support at the 50-day mean and the day low €28.60. Keltner channel middle sits at €29.00, so a reclaim above €29.50 would confirm momentum. Inventory turnover is slow, but cash per share €2.54 and net debt negative versus EBITDA support the risk-reward for a short rebound.
Meyka AI grade and analyst context
Meyka AI rates PSG.DE with a score out of 100: 75.11, Grade B+, Suggestion: BUY. This grade factors S&P 500 and sector comparison, growth, metrics, and analyst signals. Note third-party company rating shows A- with a buy bias, but valuation ratios like PB 9.12 and payout ratio over 100.00% require scrutiny.
Catalysts, sector view and key risks for PSG.DE
Catalysts include pharmacy sales growth in Germany and new OTC marketing campaigns across Europe. The Healthcare sector in Germany shows muted short-term gains, so relative outperformance would matter. Main risks are high PB, long inventory days of 400.36, and possible margin pressure from FX or distribution costs.
Trade plan, targets and risk controls
For an intraday oversold-bounce trade we suggest entry near €28.70–€28.90. Set a near-term price target of €31.50 and a hard stop at €27.50. That target implies an upside of 8.62% vs the current €29.00. Keep position sizes limited because PB and inventory metrics raise medium-term valuation risk.
Final Thoughts
We view PSG.DE stock at €29.00 as an intraday oversold-bounce candidate, trading close to its 50-day mean €28.52 and on elevated volume 12,424.00. Fundamental strength includes EPS €1.68, ROE 44.29%, and low net debt, which support a quick mean reversion. Meyka AI’s forecast model projects a yearly level of €27.36, a 3‑year level of €29.48, and a 5‑year level of €31.56. Versus the current price, that implies -5.68%, +1.65%, and +8.81% respectively. Our short-term technical target is €31.50 with a stop at €27.50, implying a near-term upside of 8.62%. Forecasts are model-based projections and not guarantees. We note valuation pressures including a high PB 9.12 and long days-of-inventory 400.36, so traders should size positions and use stops. For further company details visit the issuer site PharmaSGP and profile data at FinancialModelingPrep. Meyka AI provides this as an AI-powered market analysis platform and these views are for informational purposes only.
FAQs
Is PSG.DE stock a buy today for an oversold bounce?
PSG.DE stock shows an intraday bounce setup near €28.52 support. For traders, a tight entry with a stop at €27.50 and target €31.50 suits a short-term trade. Size positions carefully because valuation metrics are high.
What are the main risks for PharmaSGP Holding SE (PSG.DE)?
Key risks include high price-to-book 9.12, very long inventory days 400.36, and a payout ratio above 100.00%. These raise medium-term valuation and cash distribution concerns.
How does Meyka AI view PSG.DE long term?
Meyka AI’s forecast model projects €31.56 in five years. That implies a +8.81% upside from €29.00. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
